Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2

被引：1

作者：

Van Bezooijen R.L. ^{[1
,4
]}

Goey H. ^{[2
]}

Stoter G. ^{[2
]}

Hermans J. ^{[3
]}

Fleuren G.J. ^{[1
]}

机构：

[1] Department of Pathology, Leiden University Hospital

[2] Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital

[3] Department of Medical Statistics, Leiden University

[4] Department of Endocrinology, Bldg. 1, C4-R86, Leiden University Hospital, 2300 RC, Leiden

来源：

Cancer Immunology, Immunotherapy | 1997年 / 43卷 / 5期

关键词：

DNA ploidy; HLA-II; IL-2; immunotherapy; macrophages; renal cell carcinoma;

D O I：

10.1007/s002620050336

中图分类号：

学科分类号：

摘要：

Interleukin-2 (IL-2)-based immunotherapy can induce antitumor responses in about 25% of patients with metastatic renal cell carcinoma (RCC). The limited effect and the severe side-effects of IL-2 have led us to perform a prognostic factor analysis. Twenty-four patients with metastatic RCC were treated with IL-2. Flow cytometry and immunohistology were used to determine DNA ploidy, HLA-II expression on tumor cells, and the presence of macrophages in the primary tumor. These variables were examined in relation to survival. The 4-year overall survival rate was 38%. Forty-six percent of the primary tumors were aneuploid. All tumors, except one, showed HLA-II expression and macrophage presence. A statistically significant correlation (r = 0.66, P = 0.002) was found between HLA-II expression and macrophage presence. Patients with high HLA-II expression had a lower 4-year survival (22% compared to 50%), as had patients with high macrophage presence (20% compared to 42%). Of note, patients characterized by both high HLA-II and high macrophage expression had the worst survival (13% compared to 50%). We concluded that DNA ploidy was not predictive for survival, whereas HLA-II expression and macrophage presence may represent valuable prognostic factors related to survival. The present data suggest that more of the patients with no or moderate HLA-II expression and/or no or moderate macrophage presence in the primary tumor could survive with persistance of their malignant disease after having received IL-2 immunotherapy, as compared to patients with both high HLA-II and high macrophage expression.

引用

页码：293 / 298

页数：5

共 37 条

[1]

Baisch H., Otto U., Kloppel G., Malignancy index based on flow cytometry and histology for renal cell carcinomas and its correlation to prognosis, Cytometry, 7, (1986)

[2]

Banner B.F., Burnham J.A., Bahnson R.R., Ernstoff M.S., Auerbach H.E., Immunophenotypic markers in renal cell carcinoma, Mod Pathol, 3, (1990)

[3]

Beniers A.J.M.C., Peelen W.P., Debruyne F.M.J., Schalken J.A., HLA-class-I and class-II expression on renal tumor xenografts and the relation to sensitivity for α IFN, γ IFN and TNF, Int J Cancer, 48, (1991)

[4]

Bot F.J., Godschalk J.C.J., Krishnadath K.K., Van Der Kwast T.H.M., Bosman F.T., Prognostic factors in renal cell carcinoma: Immunohistochemical detection of p53 protein versus clinical-pathological parameters, Int J Cancer, 57, (1994)

[5]

Brocker E.B., Suter L., Sorg C., HLA-DR antigen expression in primary melanomas of the skin, J Invest Dermatol, 82, (1984)

[6]

Brocker E.B., Suter L., Bruggen J., Ruiter D.J., Macher E., Sorg C., Phenotypic dynamics of tumor progression in human malignant melanoma, Int J Cancer, 36, (1985)

[7]

Chin J.L., Pontes J.E., Frankfurt O.S., Flow cytometric deoxyribonucleic acid analysis of primary and metastatic human renal cell carcinoma, J Urol, 133, (1985)

[8]

Cohen P.J., Lotze M.T., Roberts J.R., Rosenberg S.A., Jaffe E.S., The immunopathology of sequential tumor biopsies in patients treated with interleukin-2, Am J Pathol, 129, (1987)

[9]

Currin S.M., Lee S.E., Walther P.J., Flow cytometric assessment of deoxyribonucleic acid content in renal adenocarcinoma: Does ploidy status enhance prognostic stratification over stage alone?, J Urol, 143, (1990)

[10]

Droz D., Zacher D., Charbit L., Gogusev J., Chretien Y., Iris L., Expression of the human nephron differentiation molecules in renal cell carcinomas, Am J Pathol, 137, (1990)

← 1 2 3 4 →